Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Blood (2022) 140 (Supplement 1): 2383–2385.

https://doi.org/10.1182/blood-2022-165229

Published: 2022

Journal Articles

Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Blood (2022) 140 (Supplement 1): 10462–10464.

https://doi.org/10.1182/blood-2022-170552

Published: 2022

Journal Articles

Allogeneic Hematopoietic Cell Transplant Yields Long Term Disease Free Survival in a Significant Number of Patients with Classic Hodgkin Lymphoma

Blood (2022) 140 (Supplement 1): 12969–12970.

https://doi.org/10.1182/blood-2022-164820

Published: 2022

Journal Articles

Utility and Validity of Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) in Predicting Overall Survival and Non-Relapse Mortality in Adolescent and Young Adult Population

Blood (2022) 140 (Supplement 1): 10566–10567.

https://doi.org/10.1182/blood-2022-167509

Published: 2022

Journal Articles

Sequential Fludarabine, Ara-C, Etoposide (FLAV) Followed By Fludarabine/ Busulfan Reduced Toxicity Conditioning Is Safe and Effective Salvage for Adult Patients with Refractory Acute Myeloid Leukemia and High Risk Myelodysplasia

Blood (2021) 138 (Supplement 1): 1851.

https://doi.org/10.1182/blood-2021-152602

Published: 2021

Journal Articles

Proteomics Analysis Reveals Protein Panels That Are Associated with Prediction to Tyrosine Kinase Inhibitors Response, Bone Marrow Transplant, Survival and Disease Outcome of Chronic Myeloid Leukemia Patients

Ayodele Alaiya, MPH, MBBS, PhD, Mahmoud Aljurf, MD, Zakia Shinwari, MSc, Fahad Z. Alsharif, MB, MD, Hazza A. Alzahrani, MD, Syed Osman Ahmed, BSc, FRCPath, MBBS, MRCP, Tarek Owaidah, MD FRCPA, Amr Suleiman Hanbali, MD, Marwan Shaheen, MD, Feras Al Fraih, MD, Riad Elfakih, MD, Saud Alhayli, MD, Shahrukh Hashmi, MD, Walid Rasheed, MB, ChB, FRACP, FRCPA, Fahed Almhareb, MBBS, FACP, Naeem A. Chaudhri, MD

Blood (2018) 132 (Supplement 1): 5434.

https://doi.org/10.1182/blood-2018-99-118754

Published: 2018

Journal Articles

Young Adult Patients with Post -HCT Relapse of AML May Benefit from Aggressive Salvage and 2 nd Cellular Therapy

Syed Osman Ahmed, MRCP, FRCPath, Amna Gamil, MD, Muhamad Hitham Almahayni, MD MRCP,, Naeem A. Chaudhri, MD FACP, Fahad Alsharif, MD, Said Y Mohamad, MD, Hazza A Alzahrani, MD, Walid Rasheed, MD, Ghuzayel Aldawsari, MD, Amr Hanbali, MD, Marwan Shaheen, MD, Feras Alfraih, MD, Shad Ahmed, MD, Khaled Ibrahim, Fahed Almhareb, MD, Mahmoud Aljurf, MD MPH

Blood (2015) 126 (23): 5482.

https://doi.org/10.1182/blood.V126.23.5482.5482

Published: 2015

Journal Articles

Expression of CD56 in Acute Myeloid Leukemia (AML) Is Associated with Poor Outcome When Patients Treated with Stem Cell Transplant in Second Remission but Not in the First Remission

Naeem A. Chaudhri, MD, FACP, Fahed Almhareb, MBBS, FACP, Claudia Ulrike Walter, PhD, Randa Nounou, M.D., Salem Khalil, M.D., Nasir Bakshi, M.D., Tarek Owaidah, MD, FRCPA, Hazzaa Al Zahrani, M.D., Said Mohamed, M.D., Walid Rasheed, M.D., Fahad Alsharif, M.D., Mahmoud Aljurf, M.D., Maher Albitar, M.D.

Blood (2011) 118 (21): 4880.

https://doi.org/10.1182/blood.V118.21.4880.4880

Published: 2011

Journal Articles

FLT3 Internal Tandem Duplication and Kinase Domain Mutations Remain Poor Prognostic Markers in Intermediate Cytogenetic AML After Treatment with Transplant in First Remission

Mahmoud Aljurf, M.D., Hala Abalkhail, PhD, Fahed Almhareb, MBBS, FACP, Naeem A. Chaudhri, MD, FACP, Claudia Ulrike Walter, PhD, Mohammed Toulimat, MT, Hazzaa Al Zahrani, M.D., Salem Khalil, M.D., Said Mohamed, M.D., Walid Rasheed, M.D., Fahad Alsharif, M.D., Maher Albitar, M.D.

Blood (2011) 118 (21): 4627.

https://doi.org/10.1182/blood.V118.21.4627.4627

Published: 2011

Journal Articles

Validation of Proposed European Leukemia Net Recommendations for Standardized Reporting and Classification of Cytogenetic Risk in AML Patients Treated with Stem Cell Transplantation

Claudia Ulrike Walter, PhD, Fahed Almhareb, MBBS, FACP, Naeem A. Chaudhri, MD, FACP, Wahiba Chebbo, M.D., Shad Ahmed, M.D., Fazal Hussain, M.D., Tusneem Elhassan, Hazzaa Al Zahrani, M.D., Said Mohamed, M.D., Walid Rasheed, M.D., Fahad Alsharif, M.D., Mahmoud Aljurf, M.D., Maher Albitar, M.D.

Blood (2011) 118 (21): 4894.

https://doi.org/10.1182/blood.V118.21.4894.4894

Published: 2011

Journal Articles

Dominance of Non-CLL Phenotype of Monoclonal B-Cell Lymphocytosis (MBL) in the Middle East and An Overall MBL Prevalence Comparable to Western Countries

Maher Albitar, M.D., Faisal Rawas, MT, Randa Nounou, M.D., Nasir Bakshi, M.D., Fahed Almhareb, M.D., Hazzaa Al Zahrani, M.D., Said Mohamed, M.D., Walid Rasheed, M.D., Salem Khalil, M.D., Fahad Alsharif, M.D., Naeem A. Chaudhri, MD, FACP, Hassan El-Solh, MD, Mahmoud Aljurf, M.D.

Blood (2011) 118 (21): 4586.

https://doi.org/10.1182/blood.V118.21.4586.4586

Published: 2011

Journal Articles

Trisomy 8 Remains An Intermediate Cytogenetic Risk Factor in Patients with Acute Myeloid Leukemia (AML) Treated with Stem Cell Transplantation

Claudia Ulrike Walter, PhD, Fahed Almhareb, MBBS, FACP, Naeem A. Chaudhri, MD, FACP, Hazzaa Al Zahrani, M.D., Mohammad Bakr, M.D., Khalid Ibrahim, M.D., Fazal Hussain, M.D., Said Mohamed, M.D., Walid Rasheed, M.D., Fahad Alsharif, M.D., Mahmoud Aljurf, M.D., Maher Albitar, M.D.

Blood (2011) 118 (21): 4900.

https://doi.org/10.1182/blood.V118.21.4900.4900

Published: 2011

Journal Articles

Clinical Relevance of IDH1 and IDH2 Mutations and Single Nucleotide Polymorphism (SNP) rs11554137 in Patients with Acute Myeloid Leukemia Treated with Stem Cell Transplant in First Complete Remission

Hala Abalkhail, PhD, Naeem A. Chaudhri, MD, FACP, Claudia Ulrike Walter, PhD, Hazzaa Al Zahrani, M.D., Randa Nounou, M.D., Ola Altombakty, MT, Fahed Almhareb, MBBS, FACP, Said Mohamed, M.D., Walid Rasheed, M.D., Fahad Alsharif, M.D., Mahmoud Aljurf, M.D., Maher Albitar, M.D.

Blood (2011) 118 (21): 4643.

https://doi.org/10.1182/blood.V118.21.4643.4643

Published: 2011

Journal Articles

Rearrangements of 12p in Acute Myeloid Leukemia (AML) Remain a Significant Adverse Prognostic Marker When Patients Are Treated with Stem Cell Transplantation

Claudia Ulrike Walter, PhD, Fahed Almhareb, MBBS, FACP, Naeem A. Chaudhri, MD, FACP, Hazzaa Al Zahrani, M.D., Wahiba Chebbo, M.D., Khalid Ibrahim, M.D., Mohammad Bakr, M.D., Said Mohamed, M.D., Walid Rasheed, M.D., Fahad Alsharif, M.D., Mahmoud Aljurf, M.D., Maher Albitar, M.D.

Blood (2011) 118 (21): 4464.

https://doi.org/10.1182/blood.V118.21.4464.4464

Published: 2011

Journal Articles

The t(9;11) Confers Good Prognosis in AML Patients Treated with Stem Cell Transplantation As Compared to Non-t(9;11) and Other Adverse-Risk Abnormalities

Claudia Ulrike Walter, PhD, Fahed Almhareb, MBBS, FACP, Naeem A. Chaudhri, MD, FACP, Abu Jafar Saleh, M.D., Wahiba Chebbo, M.D., Ghada El Gohary, M.D., Hazzaa Al Zahrani, M.D., Said Mohamed, M.D., Walid Rasheed, M.D., Fahad Alsharif, M.D., Mahmoud Aljurf, M.D., Maher Albitar, M.D.

Blood (2011) 118 (21): 2527.

https://doi.org/10.1182/blood.V118.21.2527.2527

Published: 2011

Journal Articles

Chimerism Analysis of Free Circulating DNA in the Prediction of Relapse in Patients with Acute Leukemia Treated with Stem Cell Transplantation,

Mahmoud Aljurf, M.D., Hala Abalkhail, PhD, Amal Alseraihy, M.D., Mouhab Ayas, Abdullah Al-Jefri, M.D., Ali Al-Ahmari, MD, Asim F Belgaumi, MD, Claudia Ulrike Walter, PhD, Naeem A. Chaudhri, MD, FACP, Fahed Almhareb, MBBS, FACP, Hassan El-Solh, MD, Maher Albitar, M.D.

Blood (2011) 118 (21): 3533.

https://doi.org/10.1182/blood.V118.21.3533.3533

Published: 2011

Journal Articles

Lack of CD34 Expression in Acute Myeloid Leukemia (AML) Is a Favorable Prognostic Factor in Patients Treated with Stem Cell Transplant Irrespective of the Cytogenetic Risk

Fahed Almhareb, MBBS, FACP, Claudia Ulrike Walter, PhD, Randa Nounou, M.D., Salem Khalil, M.D., Nasir Bakshi, M.D., Tarek Owaidah, MD, FRCPA, Naeem A. Chaudhri, MD, FACP, Hazzaa Al Zahrani, M.D., Said Mohamed, M.D., Walid Rasheed, M.D., Fahad Alsharif, M.D., Mahmoud Aljurf, M.D., Maher Albitar, M.D.

Blood (2011) 118 (21): 1894.

https://doi.org/10.1182/blood.V118.21.1894.1894

Published: 2011

Journal Articles

CD34 Expression in Adult Acute Lymphoblastic Leukemia (ALL) Is a Favorable Prognostic Factor in Patients Treated with Stem Cell Transplant in First Remission,

Mahmoud Aljurf, M.D., Naeem A. Chaudhri, MD, FACP, Fahed Almhareb, MBBS, FACP, Claudia Ulrike Walter, PhD, Randa Nounou, M.D., Salem Khalil, M.D., Nasir Bakshi, M.D., Tarek Owaidah, MD, FRCPA, Hazzaa Al Zahrani, M.D., Said Mohamed, M.D., Walid Rasheed, M.D., Fahad Alsharif, M.D., Maher Albitar, M.D.

Blood (2011) 118 (21): 4091.

https://doi.org/10.1182/blood.V118.21.4091.4091

Published: 2011

Journal Articles

The AG Genotype of the Wilms Tumor-1 rs16754 SNP Is Associated with Poor Outcome in Pediatric AML Patients Treated with Stem Cell Transplantation but Not in Adults

Hala Abalkhail, PhD, Hassan El-Solh, MD, Amal Alseraihy, M.D., Mouhab Ayas, Ali Al-Ahmari, MD, Asim F Belgaumi, MD, Abdullah Al-Jefri, M.D., Ola Altombakty, MT, Mohammed Toulimat, MT, Fahed Almhareb, MBBS, FACP, Naeem A. Chaudhri, MD, FACP, Claudia Ulrike Walter, PhD, Mahmoud Aljurf, M.D., Maher Albitar, M.D.

Blood (2011) 118 (21): 5237.

https://doi.org/10.1182/blood.V118.21.5237.5237

Published: 2011

Journal Articles

Most Risk-Stratification Molecular Markers in Acute Myeloid Leukemia (AML) Are Rarely Found in Early Childhood AML in the Middle Eastern Population

Hala Abalkhail, PhD, Hassan El-Solh, MD, Amal Alseraihy, M.D., Asim F Belgaumi, MD, Abdullah Al-Jefri, M.D., Mouhab Ayas, Ali Al-Ahmari, MD, Fahed Almhareb, MBBS, FACP, Naeem A. Chaudhri, MD, FACP, Claudia Ulrike Walter, PhD, Mahmoud Aljurf, M.D., Maher Albitar, M.D.

Blood (2011) 118 (21): 5239.

https://doi.org/10.1182/blood.V118.21.5239.5239

Published: 2011

NARROW

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Allogeneic Hematopoietic Cell Transplant Yields Long Term Disease Free Survival in a Significant Number of Patients with Classic Hodgkin Lymphoma

Utility and Validity of Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) in Predicting Overall Survival and Non-Relapse Mortality in Adolescent and Young Adult Population

Sequential Fludarabine, Ara-C, Etoposide (FLAV) Followed By Fludarabine/ Busulfan Reduced Toxicity Conditioning Is Safe and Effective Salvage for Adult Patients with Refractory Acute Myeloid Leukemia and High Risk Myelodysplasia

Proteomics Analysis Reveals Protein Panels That Are Associated with Prediction to Tyrosine Kinase Inhibitors Response, Bone Marrow Transplant, Survival and Disease Outcome of Chronic Myeloid Leukemia Patients

Young Adult Patients with Post -HCT Relapse of AML May Benefit from Aggressive Salvage and 2 nd Cellular Therapy

Expression of CD56 in Acute Myeloid Leukemia (AML) Is Associated with Poor Outcome When Patients Treated with Stem Cell Transplant in Second Remission but Not in the First Remission

FLT3 Internal Tandem Duplication and Kinase Domain Mutations Remain Poor Prognostic Markers in Intermediate Cytogenetic AML After Treatment with Transplant in First Remission

Validation of Proposed European Leukemia Net Recommendations for Standardized Reporting and Classification of Cytogenetic Risk in AML Patients Treated with Stem Cell Transplantation

Dominance of Non-CLL Phenotype of Monoclonal B-Cell Lymphocytosis (MBL) in the Middle East and An Overall MBL Prevalence Comparable to Western Countries

Trisomy 8 Remains An Intermediate Cytogenetic Risk Factor in Patients with Acute Myeloid Leukemia (AML) Treated with Stem Cell Transplantation

Clinical Relevance of IDH1 and IDH2 Mutations and Single Nucleotide Polymorphism (SNP) rs11554137 in Patients with Acute Myeloid Leukemia Treated with Stem Cell Transplant in First Complete Remission

Rearrangements of 12p in Acute Myeloid Leukemia (AML) Remain a Significant Adverse Prognostic Marker When Patients Are Treated with Stem Cell Transplantation

The t(9;11) Confers Good Prognosis in AML Patients Treated with Stem Cell Transplantation As Compared to Non-t(9;11) and Other Adverse-Risk Abnormalities

Chimerism Analysis of Free Circulating DNA in the Prediction of Relapse in Patients with Acute Leukemia Treated with Stem Cell Transplantation,

Lack of CD34 Expression in Acute Myeloid Leukemia (AML) Is a Favorable Prognostic Factor in Patients Treated with Stem Cell Transplant Irrespective of the Cytogenetic Risk

CD34 Expression in Adult Acute Lymphoblastic Leukemia (ALL) Is a Favorable Prognostic Factor in Patients Treated with Stem Cell Transplant in First Remission,

The AG Genotype of the Wilms Tumor-1 rs16754 SNP Is Associated with Poor Outcome in Pediatric AML Patients Treated with Stem Cell Transplantation but Not in Adults

Most Risk-Stratification Molecular Markers in Acute Myeloid Leukemia (AML) Are Rarely Found in Early Childhood AML in the Middle Eastern Population

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only